Dr. Adam Fein is the Chief Executive Officer of Drug Channels Institute. He is widely regarded as the nation's leading authority on the wholesale distribution industry.  Previously, Dr. Fein was a Senior Fellow at the Wharton School of Business' Mack Center for Technological Innovation, and was named to Supply & Demand Chain Executive magazine's list of "Top Industry Analysts to Know", based on his in-depth work in the wholesale industry. He has published several books for the National Association of Wholesaler-Distributors and numerous articles about the expansion and consolidation of competition.

Dr. Adam Fein routinely presents at private corporate events, national trade conferences, executive seminars, and other national and international forums. Dr. Adam Fein has recently been cited by Inc. Magazine, Chicago Tribune, Orlando Sentinel, The Daily Deal, Marketplace, Industrial Distribution Magazine, TheStreet.com, and many other publications.

Dr. Adam Fein believes that in emerging industries, visibility of the innovating concept is a key factor that attracts early imitating firms. This has become a more prominent variable in the digital age. He notes that since business models based on emerging technologies are often unclear, the period of dramatic expansion in the number of firms preceding a shakeout is marked by experimentation, optimism, and opportunism. 

Dr. Adam Fein's view is that early competitive crowding is driven by new entrants. Since enabling firms lower barriers, in most cases it is less risky for incumbents to wait and better understand which models are likely to win out. The maturing market can often create opportunity for incumbents, as the competitive field thins during a shakeout.  Finally, Dr. Adam Fein cautions that despite the recognizable pattern of boom and bust innovation, the biggest issue for most firms is in discerning where the industry is in its lifecycle.

Consulting, Business, CEO, Chief Executive Officer (CEO), Leadership,